Trial Profile
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Curcumin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Oct 2017 Status changed from recruiting to completed.
- 21 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 May 2014 New trial record